2018 Phase 2 study of BPN14770 for Fragile X Syndrome.
2017 Phase 2a study of BPN14770
2016 $10M raised through Series A financing and NIH grants.
2016 Multiple Ascending Dose Trial of BPN14770 completed.
2016 First BPN14770 Phase 1 trial completed.
2015 BPN147700 cognition drug enters human clinical trials.
2015 $19M raised (NIH grants, contracts, and investment capital).
2014 Collaboration with Broad Institute to develop drugs to address schizophrenia.
2013 First round of Angel financing completed.
2012 National Institute of Health (NIH) Blueprint Neurotherapeutics partnership.
2011 SBIR funding from National Institute of Mental Health (NIMH) awarded.


Chairman & CEO, Tetra Discovery Partners Inc.

Dr. Mark Gurney founded Tetra Discovery Partners as a drug development company in 2011 to develop meaningful medications for large unmet needs including Alzheimer’s disease.  He has held positions in academia and within the pharma industry.  Dr. Gurney was named one of two leading inventors in the field of Alzheimer’s Disease therapeutics for his discovery of the beta-secretase, a key enzyme in the amyloid pathway that releases the A-beta peptide from the amyloid protein precursor.

Dr. Gurney’s resume with biotech companies includes work in drug discovery and development as Senior Vice President at deCODE genetics, Inc.; Director Genomics, Pharmacia Corporation; Associate Professor, Northwestern University Feinberg School of Medicine; and Assistant Professor, University of Chicago Medical School.  In addition to his work on Alzheimer’s disease, Dr. Gurney developed the SOD1-G93A transgenic mouse model of ALS.

Dr. Gurney has authored 117 peer reviewed papers that have been cited over 18,000 times and holds 36 issued patents.  He earned a PhD in neuroscience from the California Institute of Technology and an MBA from the Kellogg Graduate School of Management at Northwestern University.


Chief Business Officer, Director of the Board

Joe Collard is the Founder/CEO of Epigenetix, which uses epigenetic pathways to solve unmet medical needs including the treatment of brain cancer.  An exited entrepreneur, he also built and sold three successful science/technology companies, namely Technisource, Curna Inc., and Sumpraxis.

Mr. Collard holds a Bachelor of Business Administration degree from the University of Michigan-Flint.


Sr. VP Clinical, Regulatory & Legal Affairs

Chad has more than 25 years of experience, primarily in the areas of biotech regulatory, clinical, compliance, intellectual property, business development, litigation, and general corporate legal affairs. Prior to joining Tetra he served as the Chief Clinical & Legal Officer for Cohera Medical, where he led the clinical, regulatory and legal aspects of commercialization of the first ever approved 100% synthetic absorbable surgical adhesive. He brings intellectual property experience from the law firm of Howard and Howard, and experience from Zassi Medical and the Surgical Group of the Stryker Corporation where he held regulatory and legal related positions.

Chad holds a J.D. from Michigan State University and a bachelor’s degree in biomedical engineering from Tulane University. He also has conducted M.B.A. studies at Boston University. He is admitted to practice before the U.S. Patent and Trademark Office and is a member of the Michigan Bar.


Chief Medical Officer

Dr. Scott A. Reines has broad drug development experience obtained as a senior executive in pharmaceutical R&D.  As Senior Vice President for CNS, Pain, and Translational Medicine at Johnson & Johnson, he oversaw the development and approval of numerous medicines for the treatment of schizophrenia, Alzheimer’s disease, and the behavioral manifestations of autism.

Prior to that, Dr. Reines served at Merck as Vice President, Clinical Research, with responsibilities for Psychopharmacology, Neuropharmacology, Gastroenterology, and Ophthalmology.  While there, he oversaw the conduct of the first large, multicenter trial of a COX-2 inhibitor for prevention of Alzheimer’s disease.

Dr. Reines earned a BS magna cum laude in chemistry from Cornell University, his PhD in bio/organic chemistry from Columbia University, and his MD from Albert Einstein College of Medicine. Following this he completed a psychiatric residency at Montefiore Hospital in New York City and obtained Board certification in psychiatry.


Chief Financial Officer

Mr. Harvey Elgersma has more than 30 years of diversified experience in financial leadership. His CFO experience includes multiple mergers and acquisitions, strategies for increasing value, and developing both successful exit and growth strategies.  Mr. Elgersma has worked with Perrigo; CHS, Inc.; Hamilton Farm Bureau Cooperative, Inc. and Cumberland Swan Holding Inc.

Mr. Elgersma holds a BBA in accounting from Grand Valley State University.


Director Chemistry

Dr. Richard Nugent leads programs for the CNS application of PDE4 inhibitors for Tetra.  Prior to this work, he worked on projects aimed at treating cystic fibrosis for Flatley Discovery Labs and drug discovery projects against inflammation, osteoporosis, and metabolic diseases as well as anti-infectives and applications of siRNA for Pfizer.  He has also worked for Pharmacia and Upjohn.

Dr. Nugent earned his BS from Miami University and his PhD in organic chemistry from the University of Rochester.


Director of the Board

Paul D’Amato is an exited entrepreneur who developed and sold a retail franchise business that operated throughout the Midwest.  Currently, Mr. D’Amato is the Managing Director of Trout Creek Ventures, a venture fund that invests in early-stage technology companies.

He received his BS in computer engineering from the University of Illinois, Champagne Urbana and an MBA from the Kellogg School of Management, Northwestern University.


Director of the Board

Dr. Douglas Morton has 40 years of experience in the pharmaceutical industry. Formerly a Vice President in the Discovery Division of Pfizer, Dr. Morton also held executive positions with Pharmacia Corporation and Upjohn, Inc.

A published scientist and prolific inventor, Dr. Morton has authored or co-authored 45 peer-reviewed scientific publications and holds 43 U.S. Patents. He currently sits on the board of 5 biotechnology companies and on the advisory boards of Cleveland Clinic Innovations, Hopen Lifescience Venture Fund, and the Southwest Michigan First Life Science Fund.

Dr. Morton received his AB in chemistry from Kenyon College and his PhD in chemistry from Columbia University.


Director of the Board

Donald R. Parfet is Managing Director of Apjohn Group LLC, a business development firm focused on commercializing breakthrough opportunities in the life sciences industries. He is also General Partner of Apjohn Ventures, a venture capital fund investing in emerging private life science companies.

Mr. Parfet serves on the board of trustees of numerous charitable organizations. He is currently board chairman of the W.E. Upjohn Institute for Employment Research; board chair of Bronson Healthcare Group; and trustee and past board chair of the Kalamazoo College Board of Trustees. Additionally, Mr. Parfet serves on four public company boards of directors, namely MASCO Corporation; Rockwell Automation, Inc.; Kelly Services, Inc.; and ProNAi Therapeutics, Inc.

Mr. Parfet earned his BA degree in economics from the University of Arizona in 1975 and his MBA degree in finance from the University of Michigan in 1977.


Director of the Board

Dr. Lance Stewart serves as Senior Director of Strategy at the University of Washington’s Institute for Protein Design. With more than twenty years of experience in life sciences partnering and entrepreneurial start-up activities, Dr. Stewart has managed several multi-year collaborations in technology development and structure-based drug design.

Dr. Stewart co-founded Emerald Biostructures (now Beryllium) in 1998, which commercialized reagents and services for structure-guided drug discovery.

He earned a B.S. in biology from McMaster University (Hamilton, ON Canada), a PhD in biochemistry and virology from Cornell University, and an Executive MBA from the UW Foster School of Business.


Scientific Advisory Board

Dr. Edward M. Scolnick joined the Broad Institute of MIT in 2004 to spearhead a major research effort in psychiatric disease and in 2007 became the director of Broad’s Psychiatric Disease Program and founding director of the Stanley Center for Psychiatric Research. Dr. Scolnick served as the Stanley Center’s director for five years, and currently serves as the center’s chief scientist.

From 1982 to 2003, Dr. Scolnick served as president of Merck Research Laboratories; executive vice president for science and technology at Merck & Co., Inc.; executive director and vice president in the department of virus and cell biology and senior vice president for basic research at Merck Research Laboratories.

Prior to joining Merck, he worked at the National Cancer Institute and at the National Heart Institute.
Dr. Scolnick is an elected member of the National Academy of Sciences, the American Academy of Arts and Sciences, and the Institute of Medicine.

He served on the Board of Directors of Merck & Co., Inc. from 1997 to 2002; the Board of Councilors for the National Institute of Mental Health from 1998 to 2002; and the FDA Science Board from 2000 to 2002. He currently is a consultant for Clarus Ventures.

Dr. Scolnick holds an A.B. from Harvard College and an M.D. from Harvard University Medical School.


Scientific Advisory Board

Dr. James S. MacDonald, a co-founder of the Synergy Partners network, provides consultation in the clinical trial phase of drug development.

He retired from Schering-Plough as Executive Vice President of Preclinical Development, where he assured a steady flow of new compounds through the development pipeline by establishing effective working relationships with appropriate groups in Discovery, Pharmaceutical Sciences and Global Clinical Research. Prior to that, Dr. MacDonald was Executive Director of Toxicology at Merck Research Laboratories. During his career at both of these companies he was responsible for numerous important human medicines now registered for global marketing.

Dr. MacDonald received his undergraduate degree from DePauw University and his PhD in toxicology from the University of Cincinnati.


Scientific Advisory Board

Dr. Catherine D. Strader has more than 25 years of pharmaceutical R&D experience including executive leadership positions at both Merck and Schering-Plough. She has guided more than 50 compounds through drug discovery.

Dr. Strader began her career at Merck, where she led the team that first defined the structure-function of G-protein coupled receptors. As Executive Vice President of Discovery Research and Chief Scientific Officer for Schering-Plough, Dr. Strader had both strategic and operational responsibility for the company’s global small molecule and biologics discovery research portfolio. In 2007 Dr. Strader returned to Merck to lead an external research initiative, integrating large pharma, biotech and CRO approaches to drug discovery. She co-founded Synergy Partners to integrate the depth and breadth of experience required to effectively bring new discoveries to clinical proof of concept and beyond.

Dr. Strader received her BS in chemistry from the University of Virginia and her PhD in chemistry from the California Institute of Technology.